The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

This merger creates an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies. Akari Therapeutics, Plc has completed of the merger of Akari Therapeutics ...

The annual meeting, held in Chicago, Illinois, featured new data and best practices for patient-centered care. The American Academy of Ophthalmology (AAO) held its annual meeting at McCormick Place in ...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio.

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) have begun what is expected to be a long-term collaboration. This announcement establishes Boehringer as the first ...

Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference. Keeping a sharp eye on geographic atrophy (GA) ...

Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference. PST-611 is a first in class non-viral vectorized ...

VEGF-A therapy has revolutionized treatment and visual outcomes for patients with neovascular age-related macular degeneration (nAMD). Ranibizumab, the first anti–VEGF-A agent to be FDA approved, was ...

Although intravitreal injections are a safe and effective form of drug delivery, the need for frequent injections and the corresponding disruptions to patients’ lives can pose a significant treatment ...

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin. PulseSight Therapeutics SAS presented new data on its lead program PST-611, a DNA ...

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.